Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Radioprotectant Can Save Life After Exposure to Deadly, Whole-Body Radiation

By MedImaging International staff writers
Posted on 29 Oct 2008
Studies conducted to date have demonstrated that even though a single, subcutaneous dose of a radioprotectant/radiomitigator agent is administered about 26 hours after exposure to lethal, whole-body radiation, a comparatively high percentage of test animals survive, having received no support other than normal food and water.

"Preliminary studies suggest a wider time window may well be achievable,” stated RxBio, Inc. (Johnson City, TN, USA) chairman and CEO Dr. W. Shannon McCool, the manufactures of the agent, called Rx100.

Moreover, an enhancement of total white blood cell and platelet counts in peripheral blood and significant increase of crypt regeneration in the small intestine have been observed following treatment with Rx100. Pharmacokinetic studies have revealed that Rx100 has a long serum half-life. (Test animals in the trial received additional supportive care in the form of, for instance, antibiotics.)

According to Gabor Tigyi, M.D., Ph.D., chairman of the department of physiology at the University of Tennessee Health Science Center (Memphis, TN, USA), and coinventor of the drug, stated, "Rx100 is unique among radiation countermeasure agents in that it is an analog of an endogenous, prosurvival molecule that boosts natural mechanisms that promote and sustain cell survival while inhibiting the cascade leading to programmed cell death. While other agents shut down essential cellular-signaling mechanisms involved in radiation-induced cellular injury, tend to lack specificity, and may deliver unacceptable toxicities, Rx100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival.”

Rx100 is unique as a radioprotectant/radiomitigator in that it can be administered orally or by subcutaneous injection and it possesses a range of favorable product characteristics that make it a suitable agent for use as a radiation countermeasure. The agent is a powerful radiomitigator that also ameliorates radiation-associated hematopoietic syndrome as well as gastrointestinal syndrome.

Related Links:
RxBio

Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Biopsy Software
Affirm® Contrast
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Digital Color Doppler Ultrasound System
MS22Plus

Channels

Nuclear Medicine

view channel
Image: CXCR4-targeted PET imaging reveals hidden inflammatory activity (Diekmann, J. et al., J Nucl Med (2025). DOI: 10.2967/jnumed.125.270807)

PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack

Acute myocardial infarction can trigger lasting heart damage, yet clinicians still lack reliable tools to identify which patients will regain function and which may develop heart failure.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.